🔍

HESTERBIO - Hester Bios

📊 NSE: HESTERBIO 🏢 Pharmaceuticals - Indian - Formulations 📅 Last Updated: 12/13/2025 22:54

📢 Recent Corporate Announcements

Hester Biosciences to Divest 43.81% Stake in Texas Lifesciences for INR 92 Million

🟡 NEUTRAL ⭐ 7/10

M&A 📅 11 Mar 2026, 11:16 AM

Hester Biosciences has announced the divestment of a 43.81% equity stake in its subsidiary, Texas Lifesciences Private Limited (TLPL), for a total consideration of INR 92 million. Following the sale to Ticop Life Private Limited, Hester will retain an 11% stake, and TLPL will cease to be a subsidiary. TLPL reported a turnover of INR 285.89 million in FY 2024-25, though over 97% of its sales were internal to Hester. This move allows Hester to unlock capital while maintaining a strategic business relationship with the entity.

Divesting 43.81% stake out of 54.81% total holding in Texas Lifesciences Private Limited.
Total aggregate consideration for the sale is INR 92 million.
TLPL's FY 2024-25 turnover was INR 285.89 million with a net worth of INR 134.17 million.
Hester will maintain an 11% equity stake and continue business operations with TLPL.
The transaction is expected to be completed within three months from March 5, 2026.

💡 Investors should watch for the impact on consolidated margins since TLPL's internal sales were previously eliminated, and monitor the utilization of the INR 92 million proceeds.

Hester Biosciences to Divest 43.81% Stake in Texas Lifesciences for INR 92 Million

🟡 NEUTRAL ⭐ 7/10

M&A 📅 11 Mar 2026, 11:16 AM

Hester Biosciences has approved the divestment of a 43.81% equity stake in its subsidiary, Texas Lifesciences Private Limited (TLPL), for a total consideration of INR 92 million. Following the sale to Ticop Life Private Limited, Hester will retain an 11% stake, and TLPL will no longer be a subsidiary. TLPL reported a turnover of INR 285.89 million in FY 2024-25, though over 97% of its sales were internal to Hester. The transaction is expected to be completed within three months and represents a strategic rationalization of the company's subsidiary portfolio.

Divesting 43.81% stake in Texas Lifesciences for an aggregate value of INR 92 million
Hester will retain an 11% equity stake and continue business relations with TLPL
TLPL FY 2024-25 turnover was INR 285.89 million with a net worth of INR 134.17 million
Over 97% of TLPL's sales were internal to Hester, resulting in elimination during consolidation
The share transfer transaction is expected to be completed within a 3-month period

💡 Investors should note this as a portfolio streamlining move that unlocks INR 92 million in cash without significantly impacting consolidated revenue due to the high volume of internal sales. Monitor for any impact on procurement margins as TLPL moves from a subsidiary to an external supplier.

Hester Biosciences Re-appoints Rajiv Gandhi as CEO & MD for 3 Years with 99.54% Approval

🟢 POSITIVE ⭐ 7/10

MANAGEMENT 📅 10 Mar 2026, 05:30 PM

Hester Biosciences has announced the successful re-appointment of Mr. Rajiv Gandhi as CEO and Managing Director for a three-year term effective from April 1, 2026. The special resolution was passed via a postal ballot process with an overwhelming 99.54% of valid votes cast in favor. While the promoter group showed 100% support, a significant majority of the small institutional voting block (99.24%) voted against the resolution. This move ensures leadership continuity for the company through March 2029.

Special resolution for re-appointment of Rajiv Gandhi as CEO & MD passed with 99.54% majority.
The new term is effective for three years from April 1, 2026, to March 31, 2029.
Total valid votes cast represented 4,075,085 shares, with 4,056,419 votes in favor.
Promoter group cast 3,451,082 votes, showing 100% internal support for the leadership.
Public institutional holders showed 99.24% dissent, though this represented only 18,570 shares.

💡 Investors should take confidence in the leadership continuity which supports long-term strategic stability. No immediate action is required as the current management remains at the helm.

Hester Biosciences Proposes Re-appointment of Rajiv Gandhi as CEO & MD for 3 Years

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 04 Feb 2026, 02:23 PM

Hester Biosciences has initiated a postal ballot process to seek shareholder approval for the re-appointment of Mr. Rajiv Gandhi as CEO and Managing Director. The proposed tenure is for three years, spanning from April 1, 2026, to March 31, 2029. This move is intended to ensure leadership continuity, and the resolution is being proposed as a Special Resolution. Shareholders can participate in the remote e-voting process from February 8 to March 9, 2026.

Proposed re-appointment of Mr. Rajiv Gandhi as CEO & Managing Director for a 3-year term.
The new term is scheduled to run from April 1, 2026, through March 31, 2029.
Remote e-voting period is set for February 8, 2026, to March 9, 2026, with results by March 11.
The resolution requires approval as a Special Resolution via postal ballot.
The cut-off date for shareholder eligibility was fixed as January 30, 2026.

💡 This is a routine leadership continuity event for the promoter-led company. Investors should support the resolution to maintain management stability, though no immediate impact on stock price is expected.

Hester Biosciences Q3 FY26: PAT Surges 140% YoY; H9N2 Vaccine License Received

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 02 Feb 2026, 11:30 AM

Hester Biosciences reported a strong 140% YoY increase in standalone PAT for Q3 FY26, driven by a favorable product mix and cost discipline. While the Poultry Healthcare division grew by 32% in Q3, the Animal Healthcare division saw a 38% decline due to timing delays in government-led immunization programs. The company achieved a major regulatory milestone by receiving manufacturing licenses for the H9N2 Avian Influenza vaccine and successfully capitalized its fill/finish facility, doubling its drug product capacity.

Standalone PAT increased by 140% YoY in Q3 FY26, supported by improved operational discipline.
Poultry Healthcare division revenue grew 32% in Q3 and 17% over the 9-month period.
Received marketing and manufacturing licenses for the H9N2 Avian Influenza vaccine post-quarter end.
Capitalized a new fill/finish facility from the INR 182 crore CWIP, doubling drug product capacity.
Animal Healthcare revenue declined 38% in Q3 due to tender delays, with recovery expected in Q4 FY26.

💡 Investors should focus on the upcoming launch of the H9N2 vaccine and the resumption of government immunization tenders in Q4. The doubling of manufacturing capacity positions the company for significant scale-up in both domestic and export markets.

Hester Biosciences Q3 Standalone PAT Jumps 140% to ₹106.7M; Poultry Division Grows 32%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 30 Jan 2026, 11:38 AM

Hester Biosciences reported a robust standalone performance for Q3 FY26, with PAT surging 140% YoY to ₹106.69 million on a 12% revenue increase. The growth was primarily driven by the Poultry Healthcare division, which grew 32%, while the Animal Healthcare division faced a 38% decline due to delayed government tenders. Consolidated PAT for the quarter fell 18% to ₹93.10 million, largely due to losses in the African subsidiary. However, the company has doubled its drug product capacity and expects a strong Q4 as national immunization programs resume.

Standalone Q3 PAT rose 140% to ₹106.69 million, while standalone revenue grew 12% to ₹703.54 million.
Poultry Healthcare division delivered 32% growth in Q3, supported by a new H9N2 Avian Influenza vaccine license.
Animal Healthcare revenue declined 38% due to deferred government orders, which are scheduled to commence in February 2026.
Consolidated 9M FY26 PAT stands at ₹409.37 million, representing a 50% growth over the previous year.
Capitalized a new fill-finish facility during the quarter, effectively doubling the company's drug product capacity.

💡 Investors should view the standalone margin expansion and poultry segment growth as positive indicators of operational efficiency. The temporary dip in animal healthcare revenue is expected to reverse in Q4, making the current performance a strong base for year-end results.

Hester Biosciences Q3 Standalone PAT Surges 140% YoY to ₹106.7 Mn; CEO Re-appointed

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 30 Jan 2026, 11:26 AM

Hester Biosciences delivered a robust standalone performance for Q3 FY26, with Net Profit jumping 140% YoY to ₹106.69 million. Standalone revenue grew by 12% YoY, driven primarily by a 32% growth in the Poultry Healthcare segment. However, consolidated PAT declined by 18% YoY to ₹93.10 million, largely due to a sharp reduction in 'Other Income' compared to the previous year. The board also confirmed the re-appointment of founder Rajiv Gandhi as CEO and Managing Director for a three-year term starting April 2026.

Standalone Revenue from Operations increased 12% YoY to ₹703.54 million in Q3 FY26.
Standalone Net Profit (PAT) rose 140% YoY to ₹106.69 million from ₹44.39 million.
Poultry Healthcare segment revenue grew 32% YoY to ₹513.02 million.
Consolidated PAT fell 18% YoY to ₹93.10 million, impacted by lower other income of ₹6.69 million vs ₹78.09 million YoY.
Mr. Rajiv Gandhi re-appointed as CEO & Managing Director for 3 years effective April 1, 2026.

💡 Investors should take note of the strong operational recovery in the standalone business and the significant growth in the poultry segment. The re-appointment of the founder-CEO ensures leadership continuity, making the stock a 'Watch' for sustained margin improvement.

Hester Biosciences Receives Manufacturing License for H9N2 Avian Influenza Vaccine

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 24 Jan 2026, 05:07 PM

Hester Biosciences has received a manufacturing license from the Food & Drugs Control Administration for its Low Pathogenic Avian Influenza (H9N2) vaccine for poultry. The H9N2 strain is a persistent challenge in the poultry industry, causing significant economic losses through reduced egg production and broiler performance. This vaccine was developed using technology acquired from ICAR-NIHSAD via Agrinnovate India. This regulatory milestone strengthens Hester's poultry healthcare portfolio and addresses a year-round comorbidity issue in the sector.

Received manufacturing and marketing license from FDCA for Inactivated Avian Influenza H9N2 vaccine.
Technology for the vaccine was acquired from ICAR-NIHSAD through Agrinnovate India.
Targets the H9N2 strain which causes significant economic losses in both layer and broiler poultry segments.
The vaccine aims to prevent irreversible drops in egg production and high mortality rates associated with the virus.
Strengthens the company's prevention-led poultry healthcare product pipeline.

💡 Investors should view this as a positive development that expands Hester's product offerings in the animal healthcare market. Monitor the commercial launch timeline and the subsequent impact on the poultry segment's revenue growth.

Hester Biosciences to Hold Q3 & 9M FY26 Earnings Call on January 30, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 23 Jan 2026, 02:11 PM

Hester Biosciences has scheduled its earnings conference call for Friday, January 30, 2026, at 2:00 PM IST. The call will discuss the financial results for the third quarter and nine-month period ending December 31, 2025. Senior management, including the CEO, Executive Director, and CFO, will be present to interact with investors. This is a standard regulatory disclosure following the conclusion of the December quarter.

Conference call scheduled for January 30, 2026, at 14:00 hrs IST.
Management representation includes CEO Rajiv Gandhi and CFO Ashish Desai.
The call covers financial performance for Q3 and 9M FY26 ending December 31, 2025.
Interaction coordinated by ICICI Securities with Diamond Pass registration available.

💡 Investors should monitor the financial results released prior to the call and listen for management commentary on animal vaccine demand and margin outlook.

Hester Biosciences Submits SEBI Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 08 Jan 2026, 12:10 PM

Hester Biosciences has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2025. The filing confirms that the company's Registrar and Share Transfer Agent, MUFG Link Intime India Private Limited, has processed all dematerialization and rematerialization requests. The report verifies that physical certificates were mutilated and cancelled after due verification, and the names of depositories were updated in the register of members. This is a standard procedural filing required to maintain regulatory transparency regarding shareholding formats.

Compliance certificate issued for the quarter ended December 31, 2025.
Registrar MUFG Link Intime India Private Limited confirmed the processing of all security certificates.
Physical certificates were cancelled and substituted in the register of members within prescribed timelines.
Securities involved are confirmed to be listed on both BSE and NSE.

💡 No action is required as this is a routine regulatory filing. Investors should continue to monitor the company's upcoming quarterly financial performance for material impact.

Hester Biosciences Closes Trading Window from Jan 1, 2026 for Q3 FY26 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 30 Dec 2025, 09:14 AM

Hester Biosciences Limited has announced the closure of its trading window starting January 1, 2026, in compliance with SEBI Insider Trading regulations. This closure is a standard procedure ahead of the announcement of financial results for the quarter and nine-month period ending December 31, 2025. The window will remain closed for all designated persons, including directors and promoters, until 48 hours after the results are made public. This filing is administrative in nature and does not reflect on the company's operational performance.

Trading window closure effective from January 1, 2026
Relates to financial results for the quarter and nine months ended December 31, 2025
Window to reopen 48 hours after the public announcement of financial results
Applies to Directors, Promoters, Designated Employees, and Specified Connected Persons

💡 No action is required as this is a routine regulatory compliance filing. Investors should wait for the official announcement of the Q3 results date to evaluate the company's performance.

View All HESTERBIO Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Standalone divisional product sales for Q2 FY26 stood at INR 64 Cr, a 12% decline YoY. H1 FY26 sales were INR 128 Cr, down 13% YoY. Consolidated Revenue from Operations for FY25 was INR 311.10 Cr, up 2.15% from INR 304.55 Cr in FY24.

Geographic Revenue Split

International consolidated division product sales were INR 155 Cr (7% degrowth YoY). Central Africa H1 FY26 revenue was INR 23 Cr. Nepal H1 FY26 revenue was INR 5.6 Cr. International markets are critical for growth but currently face institutional order delays.

Profitability Margins

Consolidated PAT margin was 6.93% in FY24 and improved to 9.46% in H1 FY25. Standalone H1 FY26 NPAT declined by 15% due to top-line pressure, though margins are being protected through process standardization.

EBITDA Margin

PBILDT margin improved significantly to 23.02% in H1 FY25 from 17.85% in FY24. Standalone H1 FY26 EBITDA declined by 13%, matching the revenue drop, indicating stable operational efficiency despite lower volumes.

Capital Expenditure

INR 182 Cr capital work in progress at the India plant is expected to be fully capitalized by March 2026. This expansion is critical to support future revenue from new products like H9N2.

Credit Rating & Borrowing

Maintains a 'Stable' outlook. Positive rating sensitivity requires TOI > INR 300 Cr and PBILDT margin > 24%. Finance costs decreased 35.7% YoY to INR 12.70 Cr in FY25 from INR 19.78 Cr in FY24.

⚙️ Operational Drivers

Raw Materials

Vaccine substrates, antigens, and animal nutrition components represent the primary raw materials, costing INR 63.95 Cr in FY25 (20.5% of revenue).

Capacity Expansion

Current expansion involves an INR 182 Cr investment in the India plant to be operational by March 2026. Tanzania plant operations are now stable and supporting the African turnaround.

Raw Material Costs

Raw material costs increased 17.7% YoY to INR 63.95 Cr in FY25 from INR 54.31 Cr in FY24, outpacing revenue growth and necessitating cost control measures.

Logistics & Distribution

Distribution is managed through marketing subsidiaries in Tanzania (HBTL) and Kenya (HBKL) and local distributors to create synergy in the African market.

📈 Strategic Growth

Expected Growth Rate

15%

Growth Strategy

Achieving growth by reducing dependency on tender-based revenue, commercializing the H9N2 vaccine for export markets, and targeting breakeven in Africa operations by FY28. The company is also exploring licensing opportunities ahead of dedicated manufacturing setups.

Products & Services

Poultry vaccines (including H9N2), animal health products, and nutrition products sold to commercial, private, and export markets.

Brand Portfolio

Hester, Texas Lifesciences (subsidiary).

New Products/Services

Commercialization of H9N2 vaccine to leverage export opportunities in markets where avian influenza control is a priority.

Market Expansion

Deepening presence in Central Africa (Tanzania, Kenya, Nigeria) and resuming institutional execution in Nepal in H2 FY26.

Market Share & Ranking

Strong presence in the poultry vaccine segment in the Indian market and growing presence in the healthcare products segment.

Strategic Alliances

Collaborative initiative with GALVmed for the VITAL program (Veterinary Innovation and Livelihood). 50% stake in Thrishool Exim Limited (Tanzania).

🌍 External Factors

Industry Trends

The industry is shifting toward specialized avian influenza control. Hester is positioning itself by commercializing H9N2 and expanding its animal healthcare segment beyond just vaccines.

Competitive Landscape

Operates in a highly regulated vaccine industry with significant competition in the poultry segment, countered by geographic diversification into Africa.

Competitive Moat

Durable advantage through a strong brand in poultry vaccines and a specialized manufacturing setup. Sustainability is supported by high entry barriers in the regulated vaccine industry.

Macro Economic Sensitivity

High sensitivity to foreign exchange; international net profit rose 99% in H1 FY26 primarily due to favorable forex movements despite a revenue decline.

Consumer Behavior

Increased focus on animal health and livelihood in emerging markets (Africa/Nepal) is driving demand for veterinary innovation.

Geopolitical Risks

Political instability and institutional delays in Africa and temporary disturbances in Nepal (August 2025) adversely affect logistics and order execution.

⚖️ Regulatory & Governance

Industry Regulations

Operates in the regulated vaccine industry requiring strict adherence to manufacturing standards and pollution norms. Audit trail features in accounting software were only enabled from February 8, 2025.

Environmental Compliance

Follows ISO 9001:2015 and ISO 14001:2015 standards for quality and environmental management.

Legal Contingencies

Provision for doubtful debts stood at INR 4.47 Cr in FY25, up from INR 0.69 Cr in FY24, indicating some collection risks.

⚠️ Risk Analysis

Key Uncertainties

Dependency on tender-based revenue (high impact on top-line stability) and the timeline for scaling up the INR 182 Cr India capex and Tanzania plant to achieve breakeven.